Effective knock down of matrix metalloproteinase-13 by an intra-articular injection of small interfering RNA (siRNA) in a murine surgically-induced osteoarthritis model

J Orthop Res. 2014 Sep;32(9):1175-80. doi: 10.1002/jor.22654. Epub 2014 May 22.

Abstract

This study investigated the effect of MMP-13 gene knock down on cartilage degradation by injecting small interfering RNA (siRNA) into knee joints in a mouse model of osteoarthritis (OA). OA was induced in male C57BL/6 mice by destabilization of medial meniscus (DMM) surgery. Change of Mmp13 expression over time was determined by qPCR analysis from 3 days to 6 weeks after surgery. Mmp13 and control chemically modified siRNA were injected into the knee joint 1 week after surgery and expression levels were assessed in synovium by qPCR 48 h later. Cartilage degradation was histologically assessed 8 weeks after DMM surgery according to OARSI recommendations. Mmp13 expression levels were elevated 1 week after surgery and peaked at 77 fold at 2 weeks compared to expression at 3 days. A 55% decrease of Mmp13 levels in cartilage was observed 48 h after injection of Mmp13 siRNA (p = 0.05). Significant reduction in the histological score at 8 weeks after surgery was observed in the Mmp13 siRNA-treated group compared to the control siRNA group (p < 0.001). Intra-articular injection of Mmp13 siRNA at the early phase of OA development resulted in effective knock down of Mmp13 expression and delay in cartilage degradation in vivo.

Keywords: DMM; MMP-13; in vivo; mouse; siRNA.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Gene Knockdown Techniques
  • Injections, Intra-Articular
  • Knee Joint / drug effects
  • Knee Joint / pathology
  • Male
  • Matrix Metalloproteinase 13 / drug effects*
  • Matrix Metalloproteinase 13 / genetics*
  • Mice
  • Mice, Inbred C57BL
  • Osteoarthritis, Knee / drug therapy*
  • Osteoarthritis, Knee / pathology
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / pharmacology*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • RNA, Small Interfering
  • Matrix Metalloproteinase 13